About US
Contact us
-
With $300M spent on potential split, Pfizer CEO now 'biased' toward branded M&ANow that Hospira's ($HSP) in the bag, Pfizer ($PFE) execs have less of an appetite for M&A in their Established Products unit. That $16 billion deal gives Pfizer added heft in injectable generics,2015/8/6
-
DME data helps Eylea soar in Q2--and poach market share from its Roche rivalsEarlier this year, Regeneron ($REGN) scored a win when its eye drugEyleaoutperformed a pair of Roche ($RHHBY) meds in a head-to-head study. And now, that win is paying off. Revenue doubled for the Ta2015/8/5
-
Baxalta to Shire: We're young, we're just starting to grow, and we're rejecting your buyout offerTuesday, Shire went public with a $30 billion bid for Baxalta that had already been rejected once. And the second time around, Baxalta had the same answer: It's not happening. Shire's $45.23-per-shar2015/8/5
-
UPDATED: India's Wockhardt recalls millions of packages of drugs in sweeping recallWhen India'sWockhardtacknowledged recently it was pulling all of the drugs still on the market that it had shipped before theFDAbanned two of its plants, it didn't say what those numbers might add up2015/8/4
-
Surprise! It's a DTC campaign for Sanofi and MannKind's AfrezzaThere's been lots of hullaballoo surrounding Sanofi ($SNY) and MannKind's ($MNKD) launch of inhaled insulinAfrezza, but for the arrival of the pair's first DTC campaign? Not so much. The companies rec2015/8/4
-
CEO Bradway, and markets, like the way Amgen's 'new product story' is shaping upAmgen ($AMGN) is only weeks away from an anticipatedFDAapproval for itsPCSK9cholesterol reducer. Already approved in Europe, the drug is expected to quickly reap blockbuster sales. As Amgen's "new pro2015/8/3
-
Ackman's 'wolf pack' drove Allergan into foreign hands, former CEO saysFormer Allergan ($AGN) CEODavid Pyottand activist investorBill Ackmancalled each other plenty of things during last year's months-long Valeant-Allergan takeover battle. But Pyott had a new one during2015/8/3
-
With solid Q2, Sanofi CEO says M&A could be part of growth strategySanofi's new CEO,Olivier Brandicourt, has a new company structure he is trotting out, a new potentially hot cholesterol-lowering drug to launch and now is able to take credit for a full quarter's wort2015/7/31
-
Celgene fights for sanction on patent challenger BassCelgene ($CELG) is hedge fund managerKyle Bass' latest patent target, it says--but the biotech isn't taking the news lying down. The New Jersey company has asked the U.S. Patent and Trademark Office2015/7/31
-
Glaxo posts 'unremarkable' results in first quarter after Novartis swapOn Wednesday, GlaxoSmithKline ($GSK) announced results for its first full quarter after closing its blockbuster asset swap with Novartis ($NVS). And so far, things look "unremarkable." That's the way2015/7/30